[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported a sale of 13,712 shares of the issuer's common stock on 08/13/2025 at a price of $15.00 per share. The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. After the reported transaction, the reporting person beneficially owned 19,631 shares, which includes an aggregate 1,778 shares acquired under the issuer's Employee Stock Purchase Plan in one or more transactions exempt under Rules 16b-3(c) and 16b-3(d). The form is signed and dated 08/15/2025.
Jonathan Allan, General Counsel e Corporate Secretary di Stoke Therapeutics, Inc. (STOK), ha comunicato la vendita di 13.712 azioni del capitale sociale dell'emittente in data 13/08/2025 al prezzo di $15,00 per azione. La comunicazione indica che la vendita 猫 stata eseguita in conformit脿 a un piano di negoziazione Rule 10b5-1 adottato dalla persona che effettua la segnalazione il 12 dicembre 2024. Dopo la transazione riportata, la persona che effettua la segnalazione deteneva beneficiariamente 19.631 azioni, comprensive di un totale di 1.778 azioni acquisite tramite il Piano di Acquisto Azionario per i Dipendenti dell'emittente in una o pi霉 operazioni esenti ai sensi delle Regole 16b-3(c) e 16b-3(d). Il modulo 猫 firmato e datato 15/08/2025.
Jonathan Allan, General Counsel y Corporate Secretary de Stoke Therapeutics, Inc. (STOK), inform贸 la venta de 13.712 acciones del capital social del emisor el 13/08/2025 a un precio de $15.00 por acci贸n. El informe se帽ala que la venta se ejecut贸 en virtud de un plan de negociaci贸n Rule 10b5-1 adoptado por la persona que informa el 12 de diciembre de 2024. Tras la operaci贸n notificada, la persona informante pose铆a beneficiariamente 19.631 acciones, que incluyen un total de 1.778 acciones adquiridas bajo el Plan de Compra de Acciones para Empleados del emisor en una o m谩s transacciones exentas seg煤n las Reglas 16b-3(c) y 16b-3(d). El formulario est谩 firmado y fechado el 15/08/2025.
Jonathan Allan, Stoke Therapeutics, Inc. (STOK)鞚� 氩曤雼措嫻 齑濌磩(General Counsel) 瓴� Corporate Secretary電� 氚滍枆須岇偓鞚� 氤错喌欤� 13,712欤�毳� 2025-08-13鞐� 欤茧嫻 $15.00鞐� 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 靹滊鞐愲姅 頃措嫻 毵る弰臧� 2024雲� 12鞗� 12鞚� 氤搓碃鞚胳澊 毂勴儩頃� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 瓯半灅 鞚错泟 氤搓碃鞚胳潃 齑� 19,631欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚� 欷� 1,778欤�電� 氚滍枆須岇偓鞚� 歆侅洂 欤检嫕毵れ垬瓿勴殟(ESPP)鞐� 霐半澕 16b-3(c) 氚� 16b-3(d) 攴滌爼鞐� 霐半澕 氅挫牅霅� 頃� 瓯� 鞚挫儊鞚� 瓯半灅搿� 旆摑霅� 欤检嫕鞛呺媹雼�. 靹滌嫕鞚� 2025-08-15鞐� 靹滊獏 氚� 旮办灛霅橃棃鞀惦媹雼�.
Jonathan Allan, General Counsel et Corporate Secretary de Stoke Therapeutics, Inc. (STOK), a d茅clar茅 la vente de 13 712 actions de l'actionnariat de l'茅metteur le 13/08/2025 au prix de 15,00 $ par action. Le d茅p么t indique que la vente a 茅t茅 r茅alis茅e en vertu d'un plan de n茅gociation Rule 10b5-1 adopt茅 par le d茅clarant le 12 d茅cembre 2024. Apr猫s la transaction signal茅e, le d茅clarant d茅tenait 脿 titre b茅n茅ficiaire 19 631 actions, y compris un total de 1 778 actions acquises dans le cadre du Plan d'Achat d'Actions pour les Employ茅s de l'茅metteur lors d'une ou plusieurs transactions exon茅r茅es en vertu des r猫gles 16b-3(c) et 16b-3(d). Le formulaire est sign茅 et dat茅 du 15/08/2025.
Jonathan Allan, General Counsel und Corporate Secretary von Stoke Therapeutics, Inc. (STOK), meldete den Verkauf von 13.712 Aktien der Stammaktien des Emittenten am 13.08.2025 zu einem Preis von $15,00 pro Aktie. Die Einreichung gibt an, dass der Verkauf gem盲脽 eines Rule-10b5-1-Handelsplans ausgef眉hrt wurde, den die meldende Person am 12. Dezember 2024 angenommen hat. Nach der gemeldeten Transaktion hielt die meldende Person wirtschaftlich 19.631 Aktien, einschlie脽lich insgesamt 1.778 Aktien, die gem盲脽 dem Employee Stock Purchase Plan des Emittenten in einer oder mehreren Transaktionen erworben wurden, die nach den Regeln 16b-3(c) und 16b-3(d) ausgenommen sind. Das Formular ist unterschrieben und datiert auf den 15.08.2025.
- Transaction executed under a Rule 10b5-1 trading plan, which documents pre-established trading intent
- Disclosure includes ESPP share detail (1,778 shares) clarifying part of the remaining holdings
- Form is signed and dated, meeting filing formalities
- Reporting person reduced direct holdings by 13,712 shares, a material disposition relative to individual position size
- No derivative activity disclosed to offset the reported disposition (options or other instruments not reported)
Insights
TL;DR: Routine insider sale under a pre-established 10b5-1 plan; no derivative activity reported.
The Form 4 discloses a direct disposition of 13,712 common shares at $15.00 executed under a Rule 10b5-1 plan adopted December 12, 2024. The filing reports remaining beneficial ownership of 19,631 shares, which includes 1,778 ESPP shares acquired in exempt transactions. There are no option exercises or other derivative transactions reported. For investors, this is a documented, planned sale by a senior officer rather than an ad hoc disposition; the filing contains clear transaction dates, prices, and the plan adoption date relevant for compliance review.
TL;DR: Disclosure aligns with Rule 10b5-1 and Section 16 reporting; timing and plan adoption are clearly stated.
The report identifies the reporting person as an officer and discloses that the sale was made pursuant to a 10b5-1 trading plan adopted on December 12, 2024, which supports the affirmative defense against insider trading claims. The Form 4 also notes ESPP-acquired shares included in total holdings and provides a manual signature dated August 15, 2025. No amendments or additional related-party filings are indicated in the document. From a governance perspective, the form contains the required information to evaluate procedural compliance.
Jonathan Allan, General Counsel e Corporate Secretary di Stoke Therapeutics, Inc. (STOK), ha comunicato la vendita di 13.712 azioni del capitale sociale dell'emittente in data 13/08/2025 al prezzo di $15,00 per azione. La comunicazione indica che la vendita 猫 stata eseguita in conformit脿 a un piano di negoziazione Rule 10b5-1 adottato dalla persona che effettua la segnalazione il 12 dicembre 2024. Dopo la transazione riportata, la persona che effettua la segnalazione deteneva beneficiariamente 19.631 azioni, comprensive di un totale di 1.778 azioni acquisite tramite il Piano di Acquisto Azionario per i Dipendenti dell'emittente in una o pi霉 operazioni esenti ai sensi delle Regole 16b-3(c) e 16b-3(d). Il modulo 猫 firmato e datato 15/08/2025.
Jonathan Allan, General Counsel y Corporate Secretary de Stoke Therapeutics, Inc. (STOK), inform贸 la venta de 13.712 acciones del capital social del emisor el 13/08/2025 a un precio de $15.00 por acci贸n. El informe se帽ala que la venta se ejecut贸 en virtud de un plan de negociaci贸n Rule 10b5-1 adoptado por la persona que informa el 12 de diciembre de 2024. Tras la operaci贸n notificada, la persona informante pose铆a beneficiariamente 19.631 acciones, que incluyen un total de 1.778 acciones adquiridas bajo el Plan de Compra de Acciones para Empleados del emisor en una o m谩s transacciones exentas seg煤n las Reglas 16b-3(c) y 16b-3(d). El formulario est谩 firmado y fechado el 15/08/2025.
Jonathan Allan, Stoke Therapeutics, Inc. (STOK)鞚� 氩曤雼措嫻 齑濌磩(General Counsel) 瓴� Corporate Secretary電� 氚滍枆須岇偓鞚� 氤错喌欤� 13,712欤�毳� 2025-08-13鞐� 欤茧嫻 $15.00鞐� 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 靹滊鞐愲姅 頃措嫻 毵る弰臧� 2024雲� 12鞗� 12鞚� 氤搓碃鞚胳澊 毂勴儩頃� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 瓯半灅 鞚错泟 氤搓碃鞚胳潃 齑� 19,631欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚� 欷� 1,778欤�電� 氚滍枆須岇偓鞚� 歆侅洂 欤检嫕毵れ垬瓿勴殟(ESPP)鞐� 霐半澕 16b-3(c) 氚� 16b-3(d) 攴滌爼鞐� 霐半澕 氅挫牅霅� 頃� 瓯� 鞚挫儊鞚� 瓯半灅搿� 旆摑霅� 欤检嫕鞛呺媹雼�. 靹滌嫕鞚� 2025-08-15鞐� 靹滊獏 氚� 旮办灛霅橃棃鞀惦媹雼�.
Jonathan Allan, General Counsel et Corporate Secretary de Stoke Therapeutics, Inc. (STOK), a d茅clar茅 la vente de 13 712 actions de l'actionnariat de l'茅metteur le 13/08/2025 au prix de 15,00 $ par action. Le d茅p么t indique que la vente a 茅t茅 r茅alis茅e en vertu d'un plan de n茅gociation Rule 10b5-1 adopt茅 par le d茅clarant le 12 d茅cembre 2024. Apr猫s la transaction signal茅e, le d茅clarant d茅tenait 脿 titre b茅n茅ficiaire 19 631 actions, y compris un total de 1 778 actions acquises dans le cadre du Plan d'Achat d'Actions pour les Employ茅s de l'茅metteur lors d'une ou plusieurs transactions exon茅r茅es en vertu des r猫gles 16b-3(c) et 16b-3(d). Le formulaire est sign茅 et dat茅 du 15/08/2025.
Jonathan Allan, General Counsel und Corporate Secretary von Stoke Therapeutics, Inc. (STOK), meldete den Verkauf von 13.712 Aktien der Stammaktien des Emittenten am 13.08.2025 zu einem Preis von $15,00 pro Aktie. Die Einreichung gibt an, dass der Verkauf gem盲脽 eines Rule-10b5-1-Handelsplans ausgef眉hrt wurde, den die meldende Person am 12. Dezember 2024 angenommen hat. Nach der gemeldeten Transaktion hielt die meldende Person wirtschaftlich 19.631 Aktien, einschlie脽lich insgesamt 1.778 Aktien, die gem盲脽 dem Employee Stock Purchase Plan des Emittenten in einer oder mehreren Transaktionen erworben wurden, die nach den Regeln 16b-3(c) und 16b-3(d) ausgenommen sind. Das Formular ist unterschrieben und datiert auf den 15.08.2025.
FAQ
What did Jonathan Allan report on Form 4 for STOK?
Was the insider sale by Jonathan Allan part of a 10b5-1 plan?
How many shares remaining include ESPP purchases?
Were any options, warrants, or other derivatives reported in this Form 4?
When was the Form 4 signed by the reporting person?
